NRG and Curium have signed a multi-year contract for the production of molybdenum-99, the starting material for technetium-99m (Tc-99m). Tc-99m is the most used isotope in nuclear medicine for diagnosing life-threatening diseases, such as cardiovascular diseases, lung and brain disorders and cancer. With this renewed collaboration 30,000 patients a day can continue to rely on the Petten nuclear medicine manufacturing capabilities.
Every year, some 49 million treatments are carried out on patients with nuclear medicines, and Tc-99m is used in more than 80% of these examinations. Both NRG and Curium are market leaders and therefore important links in the supply chain of Tc-99m. NRG uses its High Flux Reactor (HFR) to produce the isotopes, which Curium then uses for its nuclear medicine products for the benefit of the patients.
Vinod Ramnandanlal, CCO NRG PALLAS commented: “With this renewed collaboration we are taking a big step towards meeting the continuing demand and confirming our ongoing partnership. This is also particularly good news for the doctors and patients who need the isotopes."
Frank de Lange, Managing Director Curium Netherlands commented: “ This multi-year agreement confirms our commitment to doctors and patients worldwide building on our trusted legacy in nuclear medicine.”
For more information please contact